title: Quadrivalent HPV vaccine efficacy against disease related to vaccine and non-vaccine HPV types in males.
abstract: A small number of HPV types are related to a majority of HPV-related neoplastic lesions in humans. High-risk types such as HPV 16 and 18 are most often implicated, although other oncogenic and non-oncogenic HPV types can cause disease in men. The efficacy of the quadrivalent HPV vaccine (qHPV) against external genital lesions and intra-anal disease related to HPV in men has been demonstrated. This report examines the vaccine's efficacy against disease due to 10 additional non-vaccine HPV types, as well as efficacy regardless of HPV detection. The data presented suggest that vaccinating males against HPV 6, 11, 16 and 18 protects them against most vaccine HPV-type related anogenital disease. However, significant efficacy against disease due to non-vaccine HPV types was not seen. In addition, the data do not provide any evidence that vaccination with qHPV vaccine will increase the likelihood of disease caused by non-vaccine types in the short term.
authors.affiliation: Icahn School of Medicine at Mount Sinai, New York, NY, USA. segmd@prodigy.net
authors.forename: Stephen E
authors.initials: SE
authors.lastname: Goldstone
authors.forename: Heiko
authors.initials: H
authors.lastname: Jessen
authors.forename: Joel M
authors.initials: JM
authors.lastname: Palefsky
authors.forename: Anna R
authors.initials: AR
authors.lastname: Giuliano
authors.forename: Edson D
authors.initials: ED
authors.lastname: Moreira
authors.forename: Eftyhia
authors.initials: E
authors.lastname: Vardas
authors.forename: Carlos
authors.initials: C
authors.lastname: Aranda
authors.forename: Richard J
authors.initials: RJ
authors.lastname: Hillman
authors.forename: Daron G
authors.initials: DG
authors.lastname: Ferris
authors.forename: Francois
authors.initials: F
authors.lastname: Coutlee
authors.forename: J Brooke
authors.initials: JB
authors.lastname: Marshall
authors.forename: Scott
authors.initials: S
authors.lastname: Vuocolo
authors.forename: Richard M
authors.initials: RM
authors.lastname: Haupt
authors.forename: Dalya
authors.initials: D
authors.lastname: Guris
authors.forename: Elizabeth
authors.initials: E
authors.lastname: Garner
mesh_terms: D000293:Adolescent; D000328:Adult; D001003:Anal Canal / Q000473:pathology / Q000821:virology; D001005:Anus Neoplasms / Q000453:epidemiology / Q000821:virology*; D005834:Genital Neoplasms, Male / Q000473:pathology / Q000517:prevention & control / Q000821:virology; D052140:Human papillomavirus 11 / Q000472:pathogenicity; D052162:Human papillomavirus 16 / Q000472:pathogenicity; D052161:Human papillomavirus 18 / Q000472:pathogenicity; D052163:Human papillomavirus 6 / Q000472:pathogenicity; D006801:Humans; D008297:Male; D030361:Papillomavirus Infections / Q000453:epidemiology / Q000517:prevention & control* / Q000821:virology*; D053918:Papillomavirus Vaccines / Q000627:therapeutic use*; D016896:Treatment Outcome; D055815:Young Adult
chemical_list: D053918:Papillomavirus Vaccines
keywords: HPV; Males; Men who have sex with men; Young